{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:28:40Z","timestamp":1792898920268,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T00:00:00Z","timestamp":1593043200000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40801-020-00194-8","type":"journal-article","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T12:02:21Z","timestamp":1593086541000},"page":"46-54","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Real-World Use of Oritavancin for the Treatment of Osteomyelitis"],"prefix":"10.1007","volume":"7","author":[{"given":"Patrick J.","family":"Scoble","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn S.","family":"Tillotson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,25]]},"reference":[{"issue":"3","key":"194_CR1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/cir842","volume":"54","author":"B Spellberg","year":"2012","unstructured":"Spellberg B, Lipsky BA. Systemic antibiotic therapy for chronic osteomyelitis in adults. Clin Infect Dis. 2012;54(3):393\u2013407.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"194_CR2","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2106\/JBJS.N.01350","volume":"97","author":"HM Kremers","year":"2015","unstructured":"Kremers HM, Nwojo ME, Ransom JE, Wood-Wentz CM, Melton LJ 3rd, Huddleston PM 3rd. Trends in the epidemiology of osteomyelitis: a population-based study, 1969 to 2009. J Bone Jt Surg Am. 2015;97(10):837\u201345.","journal-title":"J Bone Jt Surg Am"},{"issue":"14","key":"194_CR3","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJM199704033361406","volume":"336","author":"DP Lew","year":"1997","unstructured":"Lew DP, Waldvogel FA. Osteomyelitis. N Engl J Med. 1997;336(14):999\u20131007.","journal-title":"N Engl J Med"},{"key":"194_CR4","first-page":"1457","volume-title":"Principles and practice of infectious diseases","author":"E Berbari","year":"2010","unstructured":"Berbari E, Steckelberg J, Osmon D. Osteomyelitis. In: Mandell G, Bennett J, Dolin R, editors. Principles and practice of infectious diseases. 7th ed. Philadelphia: Elsevier Inc.; 2010. p. 1457\u20131468.","edition":"7"},{"issue":"2","key":"194_CR5","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.idc.2017.01.010","volume":"31","author":"SK Schmitt","year":"2017","unstructured":"Schmitt SK. Osteomyelitis. Infect Dis Clin N Am. 2017;31(2):325\u201338.","journal-title":"Infect Dis Clin N Am"},{"issue":"9431","key":"194_CR6","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(04)16727-5","volume":"364","author":"DP Lew","year":"2004","unstructured":"Lew DP, Waldvogel FA. Osteomyelitis. Lancet. 2004;364(9431):369\u201379.","journal-title":"Lancet"},{"key":"194_CR7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/01.blo.0000088564.81746.62","volume":"414","author":"G Cierny 3rd","year":"2003","unstructured":"Cierny G 3rd, Mader JT, Penninck JJ. A clinical staging system for adult osteomyelitis. Clin Orthop Relat Res. 2003;414:7\u201324.","journal-title":"Clin Orthop Relat Res"},{"issue":"9","key":"194_CR8","first-page":"1027","volume":"84","author":"J Hatzenbuehler","year":"2011","unstructured":"Hatzenbuehler J, Pulling TJ. Diagnosis and management of osteomyelitis. Am Fam Physician. 2011;84(9):1027\u201333.","journal-title":"Am Fam Physician"},{"key":"194_CR9","volume-title":"Osteomyelitis","author":"I Momodu","year":"2019","unstructured":"Momodu I, Savaliya V. Osteomyelitis. Treasure Island: StatPearls Publishing; 2019."},{"issue":"6","key":"194_CR10","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1086\/516149","volume":"25","author":"JT Mader","year":"1997","unstructured":"Mader JT, Shirtliff M, Calhoun JH. Staging and staging application in osteomyelitis. Clin Infect Dis. 1997;25(6):1303\u20139.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 5","key":"194_CR11","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S0020-1383(11)70128-0","volume":"42","author":"G Mouzopoulos","year":"2011","unstructured":"Mouzopoulos G, Kanakaris NK, Kontakis G, Obakponovwe O, Townsend R, Giannoudis PV. Management of bone infections in adults: the surgeon's and microbiologist's perspectives. Injury. 2011;42(Suppl 5):S18\u201323.","journal-title":"Injury"},{"issue":"9","key":"194_CR12","doi-asserted-by":"crossref","first-page":"e752","DOI":"10.1016\/j.ijid.2010.01.005","volume":"14","author":"R Haidar","year":"2010","unstructured":"Haidar R, Der Boghossian A, Atiyeh B. Duration of post-surgical antibiotics in chronic osteomyelitis: empiric or evidence-based? Int J Infect Dis. 2010;14(9):e752\u2013e758758.","journal-title":"Int J Infect Dis"},{"issue":"4","key":"194_CR13","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1056\/NEJM197001222820406","volume":"282","author":"FA Waldvogel","year":"1970","unstructured":"Waldvogel FA, Medoff G, Swartz MN. Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects. N Engl J Med. 1970;282(4):198\u2013206.","journal-title":"N Engl J Med"},{"issue":"5","key":"194_CR14","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1056\/NEJM197001292820507","volume":"282","author":"FA Waldvogel","year":"1970","unstructured":"Waldvogel FA, Medoff G, Swartz MN. Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects (second of three parts). N Engl J Med. 1970;282(5):260\u20136.","journal-title":"N Engl J Med"},{"issue":"6","key":"194_CR15","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJM197002052820606","volume":"282","author":"FA Waldvogel","year":"1970","unstructured":"Waldvogel FA, Medoff G, Swartz MN. Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects. 3. Osteomyelitis associated with vascular insufficiency. N Engl J Med. 1970;282(6):316\u201322.","journal-title":"N Engl J Med."},{"issue":"3","key":"194_CR16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):285\u201392.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"194_CR17","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1086\/653519","volume":"51","author":"H Boucher","year":"2010","unstructured":"Boucher H, Miller LG, Razonable RR. Serious infections caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2010;51(Suppl 2):S183\u2013S197197.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"194_CR18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa1710926","volume":"380","author":"HK Li","year":"2019","unstructured":"Li HK, Rombach I, Zambellas R, Walker AS, McNally MA, Atkins BL, et al. Oral versus intravenous antibiotics for bone and joint infection. N Engl J Med. 2019;380(5):425\u201336.","journal-title":"N Engl J Med"},{"issue":"11","key":"194_CR19","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1592\/phco.29.11.1275","volume":"29","author":"MJ Rybak","year":"2009","unstructured":"Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC Jr, Craig WA, Billeter M, et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2009;29(11):1275\u20139.","journal-title":"Pharmacotherapy"},{"issue":"11","key":"194_CR20","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s40265-017-0764-7","volume":"77","author":"MN Jeffres","year":"2017","unstructured":"Jeffres MN. The whole price of vancomycin: toxicities, troughs, and time. Drugs. 2017;77(11):1143\u201354.","journal-title":"Drugs"},{"issue":"3","key":"194_CR21","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/jac\/dkx452","volume":"73","author":"RB Turner","year":"2018","unstructured":"Turner RB, Wilson DE, Saedi-Kwon H, Chang E, Won R, Chan D, et al. Comparative analysis of neutropenia in patients receiving prolonged treatment with ceftaroline. J Antimicrob Chemother. 2018;73(3):772\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"194_CR22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/jcpt.12030","volume":"38","author":"RP Moenster","year":"2013","unstructured":"Moenster RP, Linneman TW, Call WB, Kay CL, McEvoy TA, Sanders JL. The potential role of newer gram-positive antibiotics in the setting of osteomyelitis of adults. J Clin Pharm Ther. 2013;38(2):89\u201396.","journal-title":"J Clin Pharm Ther"},{"key":"194_CR23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2147\/CE.S33430","volume":"7","author":"RR Watkins","year":"2012","unstructured":"Watkins RR, Lemonovich TL, File TM Jr. An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy. Core Evid. 2012;7:131\u201343.","journal-title":"Core Evid"},{"issue":"8","key":"194_CR24","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1592\/phco.27.8.1189","volume":"27","author":"M Narita","year":"2007","unstructured":"Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy. 2007;27(8):1189\u201397.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"194_CR25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.amjopharm.2011.02.002","volume":"9","author":"T Bodnar","year":"2011","unstructured":"Bodnar T, Starr K, Halter JB. Linezolid-associated hypoglycemia in a 64-year-old man with type 2 diabetes. Am J Geriatr Pharmacother. 2011;9(1):88\u201392.","journal-title":"Am J Geriatr Pharmacother"},{"issue":"1\u20134","key":"194_CR26","first-page":"41","volume":"25","author":"AC Go","year":"2010","unstructured":"Go AC, Golightly LK, Barber GR, Barron MA. Linezolid interaction with serotonin reuptake inhibitors: report of two cases and incidence assessment. Drug Metabol Drug Interact. 2010;25(1\u20134):41\u20137.","journal-title":"Drug Metabol Drug Interact"},{"issue":"6","key":"194_CR27","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/jac\/dkx543","volume":"73","author":"BT Mogle","year":"2018","unstructured":"Mogle BT, Steele JM, Thomas SJ, Bohan KH, Kufel WD. Clinical review of delafloxacin: a novel anionic fluoroquinolone. J Antimicrob Chemother. 2018;73(6):1439\u201351.","journal-title":"J Antimicrob Chemother"},{"issue":"23","key":"194_CR28","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","volume":"370","author":"GR Corey","year":"2014","unstructured":"Corey GR, Kabler H, Mehra P, Gupta S, Overcash JS, Porwal A, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med. 2014;370(23):2180\u201390.","journal-title":"N Engl J Med"},{"issue":"2","key":"194_CR29","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cid\/ciu778","volume":"60","author":"GR Corey","year":"2015","unstructured":"Corey GR, Good S, Jiang H, Moeck G, Wikler M, Green S, et al. Single-dose oritavancin versus 7\u201310 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis. 2015;60(2):254\u201362.","journal-title":"Clin Infect Dis"},{"key":"194_CR30","unstructured":"Melinta Therapeutics I. Orbactiv\u00ae (oritavancin) Full Prescribing Information (Package insert). 2018."},{"issue":"6","key":"194_CR31","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1128\/AAC.00176-15","volume":"59","author":"CM Rubino","year":"2015","unstructured":"Rubino CM, Bhavnani SM, Moeck G, Bellibas SE, Ambrose PG. Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials. Antimicrob Agents Chemother. 2015;59(6):3365\u201372.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"194_CR32","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1128\/AAC.00231-09","volume":"53","author":"CM Rubino","year":"2009","unstructured":"Rubino CM, Van Wart SA, Bhavnani SM, Ambrose PG, McCollam JS, Forrest A. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Antimicrob Agents Chemother. 2009;53(10):4422\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"194_CR33","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1128\/AAC.00981-15","volume":"59","author":"D Lehoux","year":"2015","unstructured":"Lehoux D, Ostiguy V, Cadieux C, Malouin M, Belanger O, Far AR, et al. Oritavancin pharmacokinetics and bone penetration in rabbits. Antimicrob Agents Chemother. 2015;59(10):6501\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"194_CR34","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1128\/AAC.02482-13","volume":"58","author":"RE Mendes","year":"2014","unstructured":"Mendes RE, Sader HS, Flamm RK, Farrell DJ, Jones RN. Oritavancin activity against Staphylococcus aureus causing invasive infections in U.S. and European hospitals: a 5-year international surveillance program. Antimicrob Agents Chemother. 2014;58(5):2921\u20134.","journal-title":"Antimicrob Agents Chemother."},{"issue":"3","key":"194_CR35","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.diagmicrobio.2016.07.025","volume":"86","author":"LR Duncan","year":"2016","unstructured":"Duncan LR, Sader HS, Flamm RK, Jones RN, Mendes RE. Oritavancin in vitro activity against contemporary Staphylococcus aureus isolates responsible for invasive community- and healthcare-associated infections among patients in the United States (2013\u20132014). Diagn Microbiol Infect Dis. 2016;86(3):303\u20136.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"194_CR36","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/jac\/dks344","volume":"68","author":"I Morrissey","year":"2013","unstructured":"Morrissey I, Seifert H, Canton R, Nordmann P, Stefani S, Macgowan A, et al. Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and beta-haemolytic streptococci collected from western European countries in 2011. J Antimicrob Chemother. 2013;68(1):164\u20137.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"194_CR37","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1128\/AAC.00766-08","volume":"53","author":"A Belley","year":"2009","unstructured":"Belley A, Neesham-Grenon E, McKay G, Arhin FF, Harris R, Beveridge T, et al. Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Antimicrob Agents Chemother. 2009;53(3):918\u201325.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"194_CR38","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1128\/AAC.06067-11","volume":"56","author":"RE Mendes","year":"2012","unstructured":"Mendes RE, Woosley LN, Farrell DJ, Sader HS, Jones RN. Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009\u20132010. Antimicrob Agents Chemother. 2012;56(3):1639\u201342.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"194_CR39","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1002\/phar.1957","volume":"37","author":"DJ Delaportas","year":"2017","unstructured":"Delaportas DJ, Estrada SJ, Darmelio M. Successful treatment of methicillin susceptible Staphylococcus aureus osteomyelitis with oritavancin. Pharmacotherapy. 2017;37(8):e90\u2013e9292.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"194_CR40","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/phar.2057","volume":"38","author":"LT Schulz","year":"2018","unstructured":"Schulz LT, Dworkin E, Dela-Pena J, Rose WE. Multiple-dose oritavancin evaluation in a retrospective cohort of patients with complicated infections. Pharmacotherapy. 2018;38(1):152\u20139.","journal-title":"Pharmacotherapy"},{"issue":"3","key":"194_CR41","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/IPC.0000000000000599","volume":"26","author":"M Ruggero","year":"2018","unstructured":"Ruggero M, Ziegler M, Tebas P, Binkley A, Kelly B. Successful treatment of Methicillin-resistant Staphylococcus aureus vertebral osteomyelitis with outpatient oritavancin therapy. Infect Dis Clin Pract. 2018;26(3):141\u20134.","journal-title":"Infect Dis Clin Pract"},{"issue":"2","key":"194_CR42","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40121-017-0156-z","volume":"6","author":"CL Stewart","year":"2017","unstructured":"Stewart CL, Turner MS, Frens JJ, Snider CB, Smith JR. Real-world experience with oritavancin therapy in invasive gram-positive infections. Infect Dis Ther. 2017;6(2):277\u201389.","journal-title":"Infect Dis Ther"},{"issue":"7","key":"194_CR43","doi-asserted-by":"crossref","first-page":"e02622-18","DOI":"10.1128\/AAC.02622-18","volume":"63","author":"S Dahesh","year":"2019","unstructured":"Dahesh S, Wong B, Nizet V, Sakoulas G, Tran TT, Aitken SL. Treatment of multidrug-resistant vancomycin-resistant enterococcus faecium hardware-associated vertebral osteomyelitis with oritavancin plus ampicillin. Antimicrob Agents Chemother. 2019;63(7):e02622-18.","journal-title":"Antimicrob Agents Chemother."},{"issue":"4","key":"194_CR44","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ijantimicag.2018.11.023","volume":"53","author":"DB Chastain","year":"2019","unstructured":"Chastain DB, Davis A. Treatment of chronic osteomyelitis with multidose oritavancin: a case series and literature review. Int J Antimicrob Agents. 2019;53(4):429\u201334.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"194_CR45","first-page":"1","volume":"26","author":"R Foster","year":"2017","unstructured":"Foster R, Philavong K, Weissman S, Tang X, Bookstaver B. Oritavancin for treatment of daptomycin nonsusceptible vancomycin-resistant enterococci osteomyelitis. Infect Dis Clin Pract. 2017;26(2):1.","journal-title":"Infect Dis Clin Pract"},{"key":"194_CR46","unstructured":"Melinta Therapeutics I. Clinical and Historic Registry and Orbactiv Medical Evaluation (CHROME) registry. 2018."},{"issue":"5","key":"194_CR47","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.semarthrit.2006.09.004","volume":"36","author":"F Roblot","year":"2007","unstructured":"Roblot F, Besnier JM, Juhel L, Vidal C, Ragot S, Bastides F, et al. Optimal duration of antibiotic therapy in vertebral osteomyelitis. Semin Arthritis Rheum. 2007;36(5):269\u201377.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"194_CR48","doi-asserted-by":"crossref","first-page":"e00084-17","DOI":"10.1128\/CMR.00084-17","volume":"31","author":"N Kavanagh","year":"2018","unstructured":"Kavanagh N, Ryan EJ, Widaa A, Sexton G, Fennell J, O'Rourke S, et al. Staphylococcal osteomyelitis: disease progression, treatment challenges, and future directions. Clin Microbiol Rev. 2018;31(2):e00084-17.","journal-title":"Clin Microbiol Rev."},{"key":"194_CR49","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3410\/M4-4","volume":"4","author":"A Dhand","year":"2012","unstructured":"Dhand A, Sakoulas G. Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates ('the MIC Creep'): implications for therapy. F1000 Med Rep. 2012;4:4.","journal-title":"F1000 Med Rep"},{"issue":"2","key":"194_CR50","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cmi.2017.06.017","volume":"24","author":"R Diaz","year":"2018","unstructured":"Diaz R, Afreixo V, Ramalheira E, Rodrigues C, Gago B. Evaluation of vancomycin MIC creep in methicillin-resistant Staphylococcus aureus infections-a systematic review and meta-analysis. Clin Microbiol Infect. 2018;24(2):97\u2013104.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"194_CR51","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40121-016-0145-7","volume":"6","author":"PJ Anastasio","year":"2017","unstructured":"Anastasio PJ, Wolthoff P, Galli A, Fan W. Single-Dose oritavancin compared to standard of care iv antibiotics for acute bacterial skin and skin structure infection in the outpatient setting: a retrospective real-world study. Infect Dis Ther. 2017;6(1):115\u201328.","journal-title":"Infect Dis Ther"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-020-00194-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-020-00194-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-020-00194-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T23:12:52Z","timestamp":1624576372000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-020-00194-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":51,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["194"],"URL":"https:\/\/doi.org\/10.1007\/s40801-020-00194-8","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"25 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received for the preparation of this manuscript. This article is part of a supplement wholly funded by Melinta Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"P.J.S. serves as a consultant for Iterum Pharmaceuticals LTD, Shionogi & Co., LTD, and Spero Therapeutics. JR receives speaker fees from Melinta Therapeutics. GST serves as consultant to Melinta Therapeutcs, Shionogi Inc, Summit plc, KBP Biosciences and Aim Max Therapeutics.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}